Shaw, M.; Pediconi, C.; McVey, D.; Mondou, E.; Quinn, J.; Chamblin, B.; Rousseau, F. (tháng 7 năm 2013). “Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials”. Dis Colon Rectum. 56 (7): 888–897. doi:10.1097/dcr.0b013e31829196d0. PMID23739196.
Wargin, W.; Thomas, H.; Clohs, L.; St-Louis, C; Ejskajaer, N.; Gutierrez, M.; Shaughnessy, L.; Kosutic, G. (2009). “Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study”. Clin Drug Investig. 29 (6): 409–18. doi:10.2165/00044011-200929060-00004. PMID19432500.
Greenwood-Van Meerveld, B.; Kriegsman, M.; Nelson, R. (tháng 11 năm 2011). “Ghrelin as a target for gastrointestinal motility disorders”. Peptides. 32 (11): 2352–6. doi:10.1016/j.peptides.2011.03.014. PMID21453735.
Fraser, GL; Venkova, K.; Hoveyda, HR; Thomas, H.; Greenwood-Van Meerveld, B. (2009). “Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus”. Eur J Pharmacol. 604: 132–137. doi:10.1016/j.ejphar.2008.12.011.
nih.gov
ncbi.nlm.nih.gov
Fraser GL, Hoveyda HR, Tannenbaum GS. Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology. 2008 Dec;149(12):6280-8. doi: 10.1210/en.2008-0804 PMID18719021
Wargin W, Thomas H, Clohs L, St-Louis C, Ejskjaer N, Gutierrez M, Shaughnessy L, Kosutic G. Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18. doi: 10.2165/00044011-200929060-00004 PMID19432500
Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ. The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial. Dis Colon Rectum. 2010 Feb;53(2):126-34. doi: 10.1007/DCR.0b013e3181b54166 PMID20087086
Greenwood-Van Meerveld B, Kriegsman M, Nelson R. Ghrelin as a target for gastrointestinal motility disorders. Peptides. 2011 Nov;32(11):2352-6. doi: 10.1016/j.peptides.2011.03.014 PMID21453735
Bochicchio G, Charlton P, Pezzullo JC, Kosutic G, Senagore A. Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data. World J Surg. 2012 Jan;36(1):39-45. doi: 10.1007/s00268-011-1335-9 PMID22072430
Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, Rousseau F. Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum. 2013 Jul;56(7):888-97. doi: 10.1097/DCR.0b013e31829196d0 PMID23739196
Hoveyda, H.R.; Marsault, E.; Gagnon, R.; Mathieu, A.P.; Vézina, M.; Landry, A.; Wang, Z.; Benakli, K.; Beaubien, S. (ngày 22 tháng 12 năm 2011). “Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic”. J Med Chem. 54: 8305–20. PMID22106937.
Shaw, M.; Pediconi, C.; McVey, D.; Mondou, E.; Quinn, J.; Chamblin, B.; Rousseau, F. (tháng 7 năm 2013). “Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials”. Dis Colon Rectum. 56 (7): 888–897. doi:10.1097/dcr.0b013e31829196d0. PMID23739196.
Wargin, W.; Thomas, H.; Clohs, L.; St-Louis, C; Ejskajaer, N.; Gutierrez, M.; Shaughnessy, L.; Kosutic, G. (2009). “Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study”. Clin Drug Investig. 29 (6): 409–18. doi:10.2165/00044011-200929060-00004. PMID19432500.
Greenwood-Van Meerveld, B.; Kriegsman, M.; Nelson, R. (tháng 11 năm 2011). “Ghrelin as a target for gastrointestinal motility disorders”. Peptides. 32 (11): 2352–6. doi:10.1016/j.peptides.2011.03.014. PMID21453735.
